3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-fluorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine | 1310692-29-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-fluorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine
• 英文别名: 3-[1-(4-Chlorophenyl)cyclopropyl]-8-(2-Fluorophenoxy)[1,2,4]triazolo[4,3-A]pyridine；3-[1-(4-chlorophenyl)cyclopropyl]-8-(2-fluorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine
• CAS: 1310692-29-5
• 化学式: C₂₁H₁₅ClFN₃O
• 分子量: 379.821
• InChiKey: OUNKWLWWQCCPIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-溴-2-氯吡啶 在 N-甲基吗啉 、 四氯化碳 、 caesium carbonate 、 N,N-二异丙基乙胺 、 三苯基膦 、 肼 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 34.59h， 生成 3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-fluorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine
  参考文献：
  名称：

  Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)

  摘要：

  Small alkyl groups and spirocyclic-aromatic rings directly attached to the left side and right side of the 1,2,4-triazolopyridines (TZP), respectively, were found to be potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase-type 1 (11β-HSD-1) enzyme. 3-(1-(4-Chlorophenyl)cyclopropyl)-8-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridine (9f) was identified as a potent inhibitor of the 11β-HSD-1 enzyme with reduced Pregnane-X receptor (PXR) transactivation activity. The binding orientation of this TZP series was revealed by X-ray crystallography structure studies.

  DOI：

  10.1021/ml500144h

文献信息

• TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
  申请人：Li James J.

  公开号：US20090203668A1

  公开（公告）日：2009-08-13

  Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R 3 , R 3a , R 3b and R 4 are defined herein.

  提供了新型化合物，它们是11-β-羟基类固醇脱氢酶I型抑制剂。11-β-羟基类固醇脱氢酶I型抑制剂在治疗、预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病方面是有用的。这些新型化合物具有以下结构：或其立体异构体或前药或其药学上可接受的盐，其中W、L、R3、R3a、R3b和R4在此定义。
• 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF
  申请人：Jacobson Peer B.

  公开号：US20110159005A1

  公开（公告）日：2011-06-30

  A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme.
• US7579360B2
  申请人：——

  公开号：US7579360B2

  公开（公告）日：2009-08-25
• US8148396B2
  申请人：——

  公开号：US8148396B2

  公开（公告）日：2012-04-03
• US8871208B2
  申请人：——

  公开号：US8871208B2

  公开（公告）日：2014-10-28